2型糖尿病与糖代谢无因果关联于心房颤动
采用两样本孟德尔随机化方法,利用全基因组关联研究汇总数据,评估2型糖尿病、空腹血糖和HbA1c对心房颤动风险的因果影响。结果显示2型糖尿病(OR 1.01,95%CI 0.98-1.03,p=0.37)、空腹血糖(OR 0.95,95%CI 0.82-1.09,p=0.49)和HbA1c(OR 1.01,95%CI 0.85-1.17,p=0.88)均与心房颤动无显著关联,不支持改善血糖可作为房颤预防策略。
要点
- 孟德尔随机化未发现2型糖尿病与房颤存在因果关联。
- 空腹血糖和HbA1c亦未显示与房颤的因果关联。
- 提示降糖药物可能不是预防房颤的有效策略。
核心结论
- 遗传决定的2型糖尿病、空腹血糖和HbA1c与心房颤动无临床显著的因果关联。
研究设计与样本
- 两样本孟德尔随机化研究,利用全基因组关联研究汇总数据构建工具变量。
主要发现
- 2型糖尿病与房颤无显著关联(OR 1.01,95%CI 0.98-1.03,p=0.37)。
- 空腹血糖与房颤无显著关联(每mmol/l,OR 0.95,95%CI 0.82-1.09,p=0.49)。
- HbA1c与房颤无显著关联(每mmol/mol[%],OR 1.01,95%CI 0.85-1.17,p=0.88)。
- 检测2型糖尿病、空腹血糖和HbA1c与房颤关联的统计功效>80%对应的OR阈值分别为1.08、1.06和1.09。
临床怎么用
- 降糖治疗不应以预防心房颤动为主要目标。
- 房颤预防策略应关注血糖之外的其他危险因素。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS/HYPOTHESIS: Several epidemiological studies have shown an increased risk of atrial fibrillation in individuals with type 2 diabetes or milder forms of dysglycaemia. We aimed to assess whether this relation is causal using a Mendelian randomisation approach. METHODS: Two-sample Mendelian randomisation was used to obtain estimates of the influence of type 2 diabetes, fasting blood glucose (FBG), and HbA1c on the risk of atrial fibrillation. Instrumental variables were constructed using available summary statistics from meta-analyses of genome-wide association studies (GWAS) for type 2 diabetes and associated phenotypes. Pleiotropic SNPs were excluded from the analyses. The most recent GWAS meta-analysis summary statistics for atrial fibrillation, which included over 1 million individuals (approximately 60,000 individuals with atrial fibrillation) was used for outcome analysis. RESULTS: Neither type 2 diabetes (OR 1.01 [95% CI 0.98, 1.03]; p = 0.37), nor FBG (OR 0.95 [95% CI 0.82, 1.09] per mmol/l; p = 0.49) or HbA1c (OR 1.01 [95% CI, 0.85, 1.17] per mmol/mol [%]; p = 0.88) were associated with atrial fibrillation in Mendelian randomisation analyses. We had >80% statistical power to detect ORs of 1.08, 1.06 and 1.09 or larger for type 2 diabetes, FBG and HbA1c, respectively, for associations with atrial fibrillation. CONCLUSIONS/INTERPRETATION: This Mendelian randomisation analysis does not support a causal role of clinical significance between genetically programmed type 2 diabetes, FBG or HbA1c and development of atrial fibrillation. These data suggest that drug treatment to reduce dysglycaemia is unlikely to be an effective strategy for atrial fibrillation prevention. DATA AVAILABILITY: The datasets analysed during the current study are available from the following repository: Nielsen JB, Thorolfsdottir RB, Fritsche LG, et al (2018) GWAS summary statistics for AF (N=60,620 AF cases and 970,216 controls). Center for Statistical Genetics: http://csg.sph.umich.edu/willer/public/afib2018/nielsen-thorolfsdottir-willer-NG2018-AFib-gwas-summary-statistics.tbl.gz.
引用
- Harati H, Zanetti D, Rao A, et al. No evidence of a causal association of type 2 diabetes and glucose metabolism with atrial fibrillation. Diabetologia. 2019. PMID: 30810766. doi:10.1007/s00125-019-4836-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。